# Ranjit S Bindra

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 99 papers | 6,788 citations | 101496 36 h-index | 64755 79 g-index |
| 106 all docs | 106 docs citations | 106 times ranked | 9529 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Oncometabolites as Regulators of DNA Damage Response and Repair. Seminars in Radiation Oncology, 2022, 32, 82-94. | 1.0 | 3 |
| 2 | Introduction: Progress Towards Genomically-directed Radiosensitization. Seminars in Radiation Oncology, 2022, 32, 1-2. | 1.0 | 1 |
| 3 | Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100949. | 0.6 | 1 |
| 4 | In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia, 2022, 36, 1313-1323. | 3.3 | 11 |
| 5 | Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma. Scientific Reports, 2022, 12, 5827. | 1.6 | 9 |
| 6 | TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular Cancer Therapeutics, 2022, 21, 1090-1102. | 1.9 | 13 |
| 7 | Intrathecal delivery and its applications in leptomeningeal disease. Advanced Drug Delivery Reviews, 2022, 186, 114338. | 6.6 | 9 |
| 8 | MicroRNA miR-24-3p reduces DNA damage responses, apoptosis, and susceptibility to chronic obstructive pulmonary disease. JCI Insight, 2021, 6, . | 2.3 | 16 |
| 9 | Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology, 2021, 5, 466-472. | 1.5 | 24 |
| 10 | Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore. Oncotarget, 2021, 12, 891-906. | 0.8 | 1 |
| 11 | Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity. NAR Cancer, 2021, 3, zcab021. | 1.6 | 16 |
| 12 | The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance. Neurosurgery Clinics of North America, 2021, 32, 171-180. | 0.8 | 9 |
| 13 | Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. NAR Cancer, 2021, 3, zcab018. | 1.6 | 17 |
| 14 | Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nature Biomedical Engineering, 2021, 5, 1048-1058. | 11.6 | 96 |
| 15 | Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity. Translational Oncology, 2021, 14, 101147. | 1.7 | 28 |
| 16 | Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, 343-357. | 1.3 | 7 |
| 17 | Abstract P055: Targeting Krebs-cycle-deficient renal cell carcinoma with PARP inhibitor and low-dose alkylating chemotherapy. , 2021, , . | | 0 |
| 18 | LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy. Nature Cell Biology, 2020, 22, 1276-1285. | 4.6 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Penetrating the brain tumor space with DNA damage response inhibitors. Neuro-Oncology, 2020, 22, 1718-1720. | 0.6 | 1 |
| 20 | Microcephalin 1/BRIT1-TRF2 interaction promotes telomere replication and repair, linking telomere dysfunction to primary microcephaly. Nature Communications, 2020, 11, 5861. | 5.8 | 13 |
| 21 | Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature, 2020, 582, 586-591. | 13.7 | 183 |
| 22 | Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer. Cancer, 2020, 126, 3657-3666. | 2.0 | 18 |
| 23 | Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma. Npj Genomic Medicine, 2020, 5, 23. | 1.7 | 3 |
| 24 | Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortiumâ€™s first workshop on CNS drug delivery. Neuro-Oncology, 2020, 22, 1422-1424. | 0.6 | 22 |
| 25 | Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 96-103. | 1.8 | 6 |
| 26 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113. | 0.6 | 543 |
| 27 | DNMT3A co-mutation in an IDH1-mutant glioblastoma. Journal of Physical Education and Sports Management, 2019, 5, a004119. | 0.5 | 6 |
| 28 | Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry. Scientific Reports, 2019, 9, 11238. | 1.6 | 8 |
| 29 | Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. Cancer Research, 2019, 79, 4331-4338. | 0.4 | 44 |
| 30 | PPM1D mutations silence NAPRT geneÂexpression and confer NAMPT inhibitor sensitivity in glioma. Nature Communications, 2019, 10, 3790. | 5.8 | 54 |
| 31 | Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. Nature Reviews Clinical Oncology, 2019, 16, 521-522. | 12.5 | 3 |
| 32 | Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research, 2019, 39, 2911-2918. | 0.5 | 8 |
| 33 | Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452â€“8. European Urology, 2019, 76, e109-e110. | 0.9 | 4 |
| 34 | Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials. Journal of Radiation Oncology, 2019, 8, 39-46. | 0.7 | 0 |
| 35 | Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review. Advances in Radiation Oncology, 2019, 4, 520-531. | 0.6 | 69 |
| 36 | Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials, 2019, 201, 87-98. | 5.7 | 77 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | EXTH-55. TEMOZOLOMIDE-RESISTANT GLIOMA CELLS ARE SENSITIVE TO CHLOROETHYLATING NITROSOUREA COMPOUNDS IN COMBINATION WITH ATR INHIBITORS. Neuro-Oncology, 2019, 21, vi94-vi94. | 0.6 | 0 |
| 38 | RDNA-06. TARGETING IDH1/2-MUTANT GLIOMAS WITH UNIQUE COMBINATIONS OF DNA REPAIR INHIBITORS. Neuro-Oncology, 2019, 21, vi208-vi208. | 0.6 | 0 |
| 39 | Targeting DNA repair in gliomas. Current Opinion in Neurology, 2019, 32, 878-885. | 1.8 | 11 |
| 40 | The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2019, 134, 3909-3909. | 0.6 | 5 |
| 41 | PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors. Blood, 2019, 134, 4222-4222. | 0.6 | 3 |
| 42 | Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatric Blood and Cancer, 2018, 65, e26969. | 0.8 | 35 |
| 43 | Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. Lancet Oncology, The, 2018, 19, 23-24. | 5.1 | 7 |
| 44 | Introduction to the Yale Precision Medicine Tumor Board. Lancet Oncology, The, 2018, 19, 19-20. | 5.1 | 3 |
| 45 | DNA polymerase beta participates in DNA End-joining. Nucleic Acids Research, 2018, 46, 242-255. | 6.5 | 181 |
| 46 | Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. Clinical Cancer Research, 2018, 24, 1073-1081. | 3.2 | 297 |
| 47 | Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. Journal of Neuro-Oncology, 2018, 136, 289-298. | 1.4 | 4 |
| 48 | The Higher the Grade, the Bigger the Field. International Journal of Radiation Oncology Biology Physics, 2018, 102, 488-489. | 0.4 | 0 |
| 49 | Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Research, 2018, 78, 6539-6548. | 0.4 | 12 |
| 50 | CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2018, 8, 95. | 1.3 | 36 |
| 51 | Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nature Genetics, 2018, 50, 1086-1092. | 9.4 | 152 |
| 52 | Biodegradable PEG-poly(Ï‰-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. Biomaterials, 2018, 178, 193-203. | 5.7 | 43 |
| 53 | Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology, 2017, 19, now150. | 0.6 | 38 |
| 54 | 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Science Translational Medicine, 2017, 9, . | 5.8 | 420 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The role of radiation in treating glioblastoma: here to stay. Journal of Neuro-Oncology, 2017, 134, 479-485. | 1.4 | 26 |
| 56 | Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas. Molecular Cancer Therapeutics, 2017, 16, 1456-1469. | 1.9 | 26 |
| 57 | Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. Journal of Neuro-Oncology, 2017, 134, 541-549. | 1.4 | 109 |
| 58 | Biâ€allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. Journal of Pathology, 2017, 242, 165-177. | 2.1 | 43 |
| 59 | Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Radiotherapy and Oncology, 2017, 125, 258-265. | 0.3 | 3 |
| 60 | SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. Cell Reports, 2017, 20, 1921-1935. | 2.9 | 147 |
| 61 | GBM radiosensitizers: dead in the waterâ€¦ or just the beginning?. Journal of Neuro-Oncology, 2017, 134, 513-521. | 1.4 | 19 |
| 62 | State of the art: the evolving role of RT in combined modality therapy for GBM. Journal of Neuro-Oncology, 2017, 134, 477-478. | 1.4 | 0 |
| 63 | CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis.. Journal of Clinical Oncology, 2017, 35, 6060-6060. | 0.8 | 1 |
| 64 | Induction of a BRCAness state by oncometabolites and exploitation by PARP inhibitors.. Journal of Clinical Oncology, 2017, 35, 11586-11586. | 0.8 | 0 |
| 65 | Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. JAMA Oncology, 2016, 2, 1574. | 3.4 | 47 |
| 66 | PEGylated squalenoyl-gemcitabine nanoparticles for the treatment ofÂglioblastoma. Biomaterials, 2016, 105, 136-144. | 5.7 | 55 |
| 67 | A single double-strand break system reveals repair dynamics and mechanisms in heterochromatin and euchromatin. Genes and Development, 2016, 30, 1645-1657. | 2.7 | 95 |
| 68 | Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. Seminars in Radiation Oncology, 2016, 26, 281-298. | 1.0 | 23 |
| 69 | Advances in Radiation Therapy in Pediatric Neuro-oncology. Journal of Child Neurology, 2016, 31, 506-516. | 0.7 | 17 |
| 70 | Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report. Journal of Neurosurgery: Pediatrics, 2016, 17, 434-438. | 0.8 | 4 |
| 71 | Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay. Journal of the American Chemical Society, 2016, 138, 3844-3855. | 6.6 | 43 |
| 72 | A contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report. Journal of Radiosurgery and SBRT, 2016, 4, 43-52. | 0.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. Journal of Radiosurgery and SBRT, 2016, 4, 97-106. | 0.2 | 1 |
| 74 | ATNT-15MIBEFRADIL DIHYDROCHORIDE WITH HYPOFRACTIONATED RADIATION FOR RECURRENT GLIOBLASTOMA: PRELIMINARY RESULTS OF A PHASE I DOSE EXPANSION TRIAL. Neuro-Oncology, 2015, 17, v13.3-v13. | 0.6 | 0 |
| 75 | Development of a novel method to create double-strand break repair fingerprints using next-generation sequencing. DNA Repair, 2015, 26, 44-53. | 1.3 | 14 |
| 76 | Change in radiotherapy treatment volumes with initial alkylating chemotherapy in anaplastic gliomas. Journal of Radiation Oncology, 2015, 4, 163-167. | 0.7 | 0 |
| 77 | Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors. Molecular Cancer Therapeutics, 2015, 14, 326-342. | 1.9 | 36 |
| 78 | Delayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors. Pediatric Neurology, 2014, 50, 549-556. | 1.0 | 38 |
| 79 | In regards to decision making for reirradiation of a recurrent intramedullary spinal cord metastasis. Journal of Radiosurgery and SBRT, 2014, 3, 165-168. | 0.2 | 0 |
| 80 | Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells. Nucleic Acids Research, 2013, 41, e115-e115. | 6.5 | 71 |
| 81 | Targeted Disruption of the CCR5 Gene in Human Hematopoietic Stem Cells Stimulated by Peptide Nucleic Acids. Chemistry and Biology, 2011, 18, 1189-1198. | 6.2 | 54 |
| 82 | The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again. Expert Review of Anticancer Therapy, 2011, 11, 1367-1378. | 1.1 | 6 |
| 83 | Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2201-2206. | 3.3 | 193 |
| 84 | Targeting the DNA damage response for cancer therapy. DNA Repair, 2009, 8, 1153-1165. | 1.3 | 75 |
| 85 | Editorial [Hot Topic: Hypoxia and Tumor Progression (Guest Editors: Ranjit S. Bindra and Peter M.) Tj ETQq1 1 0.784314 rgBT /Overlock Molecular Medicine, 2009, 9, 399-400. | 0.6 | 1 |
| 86 | Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance. Cancer Research, 2008, 68, 605-614. | 0.4 | 286 |
| 87 | Co-repression of mismatch repair gene expression by hypoxia in cancer cells: Role of the Myc/Max network. Cancer Letters, 2007, 252, 93-103. | 3.2 | 90 |
| 88 | Hypoxia-induced genetic instabilityâ€"a calculated mechanism underlying tumor progression. Journal of Molecular Medicine, 2007, 85, 139-148. | 1.7 | 128 |
| 89 | Regulation of DNA repair in hypoxic cancer cells. Cancer and Metastasis Reviews, 2007, 26, 249-260. | 2.7 | 191 |
| 90 | Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites. Cancer Biology and Therapy, 2006, 5, 1400-1407. | 1.5 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Alterations in DNA Repair Gene Expression under Hypoxia: Elucidating the Mechanisms of Hypoxia-Induced Genetic Instability. Annals of the New York Academy of Sciences, 2005, 1059, 184-195. | 1.8 | 69 |
| 92 | Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 569, 75-85. | 0.4 | 146 |
| 93 | Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs. Cancer Research, 2005, 65, 11597-11604. | 0.4 | 313 |
| 94 | Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy and Oncology, 2005, 76, 168-176. | 0.3 | 172 |
| 95 | Hypoxia-Induced Phosphorylation of Chk2 in an Ataxia Telangiectasia Mutatedâ€“Dependent Manner. Cancer Research, 2005, 65, 10734-10741. | 0.4 | 85 |
| 96 | Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells. Molecular and Cellular Biology, 2004, 24, 8504-8518. | 1.1 | 341 |
| 97 | Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under Hypoxic Stress in Mammalian Cells. Molecular and Cellular Biology, 2003, 23, 3265-3273. | 1.1 | 255 |
| 98 | VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Research, 2002, 62, 3014-9. | 0.4 | 102 |
| 99 | Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nature Genetics, 1997, 17, 171-178. | 9.4 | 812 |